IASLC Releases Atlas of EGFR Testing in Lung Cancer
At its 2017 World Conference on Lung Cancer (WCLC) in Yokohama, Japan, the International Association for the Study of Lung Cancer (IASLC) released its Atlas of EGFR Testing in Lung Cancer. This guidebook, which will soon be available in six languages, provides health-care professionals with a wide variety of information on epidermal growth factor receptor (EGFR) testing topics, from the best tumor-sampling practices to reporting and quality assurance. This comprehensive compendium is the first version of the EGFR Testing Atlas but the third in the atlas series, joining ALK/ROS1 and PD-L1 (programmed cell death ligand 1) Testing Atlas.
“The IASLC is committed to developing and implementing global standards that make it possible for all lung cancer patients, regardless of where they live, to receive the best possible care. This guide empowers health-care professionals to utilize EGFR testing to create better outcomes for their patients,” stated David Carbone, MD, PhD; Fred Hirsch, MD, PhD; and Tony Mok, MD, editors of the guide.
Not only does the atlas provide information on EGFR testing methods, it also assists clinicians in the interpretation of the test results. Moreover, the guide contains summaries of relevant clinical data that support the use of EGFR testing in certain patients.